Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1) (ARTISTRY-1)
안정적인 복합 치료 요법에 대한 바이러스 억제 HIV-1 환자를 대상으로 빅테그라비르/레나카파비르 대 안정 기준 요법의 안전성 및 효능을 평가하기 위한 운영상 원활한 2/3상 무작위, 공개 라벨, 다기관, 능동 대조 연구
The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus current therapy (Phase 2) and BIC/LEN fixed-dose combination (FDC) versus current therapy (Phase 3) in people living with HIV (PWH).
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 2 단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Cape Town, 남아프리카, 7925
- Desmond Tutu Health Foundation Clinical Trials Unit
-
Ga-Rankuwa, 남아프리카, 208
- Sefako Makgatho Health Sciences University
-
Johannesburg, 남아프리카, 2193
- Ezintsha
-
-
-
-
-
Kaohsiung City, 대만, 80756
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
Kaohsiung City, 대만, 81362
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
New Taipei City, 대만, 22060
- Far Eastern Memorial Hospital
-
Taoyuan City, 대만, 33004
- Taoyuan General Hospital
-
-
-
-
-
Daegu, 대한민국, 41944
- Kyungpook National University Hospital
-
Daejeon, 대한민국, 35015
- Chungnam National University Hospital
-
Seoul, 대한민국, 06591
- The Catholic University of Korea Seoul St. Mary's Hospital
-
Seoul, 대한민국, 03722
- Yonsei University Severance Hospital
-
-
-
-
-
Santo Domingo, 도미니카 공화국
- Instituto Dominicano de Estudio Virologicos - IDEV
-
-
-
-
-
Berlin, 독일, 10439
- zibp Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH
-
Bonn, 독일, 53127
- Universitatsklinikum Bonn
-
Frankfurt, 독일, 60596
- Infektio Research GmbH & Co.KG
-
Hamburg, 독일, 20146
- ICH Study Center GmbH & Co. KG
-
München, 독일
- MVZ München am Goetheplatz
-
-
-
-
California
-
Berkeley, California, 미국, 48072
- Be Well Medical Center
-
Beverly Hills, California, 미국, 90211
- Pacific Oaks Medical Group
-
Los Angeles, California, 미국, 90036
- Ruane Clinical Research Group, Inc
-
Oakland, California, 미국, 94609
- Alta Bates Summit Medical Center, Summit Campus, East Bay Advanced Care
-
Palm Springs, California, 미국, 92262
- Bios Clinical Research
-
San Diego, California, 미국, 92103
- University of California San Diego (UCSD)
-
Torrance, California, 미국, 90502
- Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center
-
West Hollywood, California, 미국, 90046
- The Men's Health Foundation
-
-
Colorado
-
Denver, Colorado, 미국, 80204
- Denver Health Medical Center
-
-
Connecticut
-
New Haven, Connecticut, 미국, 06510
- Yale University; School of Medicine; AIDS Program
-
-
Florida
-
DeLand, Florida, 미국, 32720
- Midland Florida Clinical Research Center, LLC
-
Fort Lauderdale, Florida, 미국, 33316
- Gary Richmond, MD, PA, Inc.
-
Fort Lauderdale, Florida, 미국, 33308
- Therafirst Medical Centers
-
Ft. Pierce, Florida, 미국, 34982
- Midway Immunology & Research Center, LLC
-
Miami, Florida, 미국, 33136
- Schiff Center for liver Diseases/University of Miami
-
Miami Lakes, Florida, 미국, 33016
- Floridian Clinical Research
-
Orlando, Florida, 미국, 32803
- Orlando Immunology Center
-
Orlando, Florida, 미국, 32803
- Therapeutic Concepts, PA
-
West Palm Beach, Florida, 미국, 33407
- Triple O Research Institute PA
-
-
Georgia
-
Atlanta, Georgia, 미국, 30309
- Atlanta ID Group
-
Macon, Georgia, 미국, 31201
- Mercer University School of Medicine
-
-
Illinois
-
Chicago, Illinois, 미국, 60613
- Howard Brown Health Center
-
-
Missouri
-
Kansas City, Missouri, 미국, 64111
- Kansas City Care Clinic
-
St Louis, Missouri, 미국, 63139
- Southampton Healthcare, Inc.
-
-
New Jersey
-
Newark, New Jersey, 미국, 07102
- Saint Michael's Medical Center
-
-
New Mexico
-
Santa Fe, New Mexico, 미국, 87505
- AXCES Research Group
-
-
New York
-
Flushing, New York, 미국, 11355
- New York Presbyterian Hospital
-
New York, New York, 미국, 10001
- Ricky K. Hsu, MD, PC
-
-
North Carolina
-
Chapel Hill, North Carolina, 미국, 27514
- University of North Carolina - Chapel Hill
-
Greenville, North Carolina, 미국, 27858
- East Carolina University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19107
- Philadelphia FIGHT
-
-
South Carolina
-
Charleston, South Carolina, 미국, 29425
- Medical University of South Carolina (MUSC) Research NEXUS
-
-
Texas
-
Austin, Texas, 미국, 78705
- Central Texas Clinical Research
-
Bellaire, Texas, 미국, 77401
- St. Hope Foundation
-
Dallas, Texas, 미국, 75246
- North Texas Infectious Diseases Consultants
-
Dallas, Texas, 미국, 75208
- AIDS Arms, Inc., DBA Prism Health North Texas
-
Fort Worth, Texas, 미국, 76104
- Texas Centers for Infectious Disease Associates
-
Houston, Texas, 미국, 77098
- Gordon E. Crofoot MD PA
-
Longview, Texas, 미국, 75605
- Diagnostic Clinic of Longview - Center for Clinical Research
-
-
Washington
-
Seattle, Washington, 미국, 98104
- Peter Shalit, MD
-
-
-
-
-
Barcelona, 스페인, 08036
- Hospital Clinic Provincial de Barcelona
-
Madrid, 스페인, 28040
- Hospital Clinico San Carlos
-
Madrid, 스페인, 28046
- Hospital Universitario La Paz
-
Madrid, 스페인, 28034
- Hospital Ramon y Cajal, Madrid
-
Seville, 스페인, 4103
- Hospital Universitario Virgen del Rocio
-
-
-
-
-
Buenos Aires, 아르헨티나, 1202
- Fundación Huésped
-
Buenos Aires, 아르헨티나, 1072
- Hospital General de Agudos J.M Ramon Mejia
-
Buenos Aires, 아르헨티나, 1425
- Helios Salud
-
-
-
-
-
Birmingham, 영국, B9 5SS
- Department of HIV & Sexual Medicine
-
Brighton, 영국, BN2 3EW
- Brighton and Sussex University Hospitals NHS Trust
-
London, 영국, E1 1BB.
- Barts Health NHS Trust
-
London, 영국, SE5 9RS
- HIV medicine and infectious diseases
-
London, 영국, SW109NH
- St.Stephen's AIDS Trust, Clinical Trials Unit, 1st Floor, St.Stephen's Centre
-
-
-
-
-
Milan, 이탈리아, 20157
- ASST Fatebenefratelli Sacco
-
Milan, 이탈리아, 20127
- IRCCS Ospedale San Raffaele
-
Modena, 이탈리아, 40124
- Azienda Ospedaliero-Universitaria di Modena
-
Roma, 이탈리아, 00149
- Istituto Nazionale Malattie Infettive "Lazzaro Spallanzani" IRCCS
-
Torino, 이탈리아, 10149
- ASL Città di Torino
-
-
-
-
-
Nagoya, 일본
- National Hospital Organization Nagoya Medical Center
-
Osaka, 일본, 540-0006
- National Hospital Organization Osaka National Hospital
-
Tokyo, 일본, 162-0052
- Center Hospital of the National Center for Global Health and Medicine
-
-
-
-
-
Decarie Montreal, 캐나다, H4A 3J1
- Chronic Viral Illness Service / McGill University Health Centre (MUHC)
-
Montreal, 캐나다, H2L 0B1
- Clinique Medicale du Quartier Latin
-
Ottawa, 캐나다, K1H 8L6
- The Ottawa Hospital - General Campus
-
Regina, 캐나다, S4P 0W5
- ID Clinic
-
Toronto, 캐나다, M5G 1K2
- Maple Leaf Research
-
Vancouver, 캐나다, V6Z 2T1
- Spectrum Health
-
-
-
-
PR
-
San Juan, PR, 푸에르토 리코, 00909
- Hope Clinical Research
-
San Juan, PR, 푸에르토 리코, 00935
- Proyecto ACTU
-
-
-
-
-
Nice, 프랑스, 6202
- CHU Nice-Hôpital l'Archet
-
Paris, 프랑스, 75010
- Hospital Saint Louis
-
Paris, 프랑스, 75018
- Groupe Hospitalier Bichat Claude Bernard
-
Paris, 프랑스, 75651
- Höpital de la Pitié Salpêtrière
-
-
-
-
New South Wales
-
Darlinghurst, New South Wales, 호주, 2010
- St.Vincent's Hospital Sydney
-
Darlinghurst, New South Wales, 호주, 2011
- Taylor Square Private Clinic
-
Sydney, New South Wales, 호주, 2010
- Holdsworth House Medical Practice
-
-
Victoria
-
Melbourne, Victoria, 호주, 3004
- Alfred Health
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Key Inclusion Criteria:
-
If plasma HIV-1 RNA measurements in the 6 months prior to screening are available, all levels must be < 50 copies/mL.
-
At least one documented plasma HIV-1 RNA level measured between 6 and 12 months (± 2 months) prior to screening. This and any other HIV-1 RNA measurements documented in this period must be < 50 copies/mL
-
Plasma HIV-1 RNA levels < 50 copies/mL at screening.
-
Currently receiving a complex antiretroviral (ARV) regimen due to previous viral resistance, or intolerance, or contraindication to existing single-tablet regimens (STR), and on this regimen for at least 6 months prior to the screening visit. The criteria to define a complex regimen in this study are as follows:
- A regimen containing a boosted protease inhibitor or a nonnucleos(t)ide reverse transcriptase inhibitor (NRTI) plus at least 1 other third agent (ie, an agent from a class other than NRTIs) (eg, bictegravir/emtricitabine/tenofovir alafenamide (coformulated; Biktarvy®)(BVY) + darunavir/cobicistat, BVY + etravirine), or
- A regimen of ≥ 2 pills/day, or a regimen requiring dosing more than once daily, or
- A regimen containing parenteral agent(s) (excluding a complete long-acting injectable regimen, such as intramuscular cabotegravir plus rilpivirine) as well as oral agents.
-
No documented or suspected resistance to bictegravir (BIC).
-
Estimated glomerular filtration rate ≥ 15 mL/min according to the Cockcroft-Gault formula for creatinine clearance (CLcr) who are not on renal replacement therapy.
Key Exclusion Criteria:
- Prior use of, or exposure to, lenacapavir (LEN)
- Active tuberculosis infection
- Chronic hepatitis B virus (HBV) infection
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg
Participants will switch from their Stable Baseline Regimen (SBR) to a regimen of BIC 75 mg + LEN 25 mg, tablets administered orally once daily for up to 24 weeks. Participants will receive a 2-day pharmacokinetic (PK) oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC 75 mg + LEN 25 mg starting on Day 1. Participants who discontinue early or complete the Randomized Phase (RP) will have an option to continue in Extension Period (EP) |
Tablets administered orally without regard to food
다른 이름들:
Tablets administered orally without regard to food
다른 이름들:
|
|
실험적: Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg
Participants will switch from their SBR to a regimen of BIC 75 mg + LEN 50 mg, tablets administered orally once daily for up to 24 weeks. Participants will receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC 75 mg + LEN 50 mg starting on Day 1. Participants who discontinue early or complete the RP will have an option to continue in EP. |
Tablets administered orally without regard to food
다른 이름들:
Tablets administered orally without regard to food
다른 이름들:
|
|
활성 비교기: Phase 2: Treatment Group 3: SBR
Participants will continue with their SBR for up to 24 weeks. Participants who discontinue early or complete the RP will have an option to continue in EP. |
SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).
|
|
실험적: Phase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDC
Participants will switch from their SBR to a regimen of BIC/LEN 75mg/50mg FDC, administered orally once daily for up to 48 weeks. Participants will receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC/LEN 75 mg/50 mg FDC starting on Day 1. Participants who discontinue early or complete the RP will have an option to continue in EP. |
Tablets administered orally without regard to food
다른 이름들:
|
|
활성 비교기: Phase 3: Treatment Group 2: SBR
Participants will continue with their SBR for up to 48 weeks. Participants who will discontinue early or complete the RP had an option to continue in EP. |
SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).
|
|
실험적: Phase 2/Phase 3:BIC/LEN 75/50 mg FDC
At the end of randomized treatment, participants in Phase 2 and Phase 3 treatment groups who discontinue early or complete the RP will be given an option to enter in EP and will receive BIC/LEN 75/50 mg FDC until the drug is available in market or Gilead elects to withdraw the study. Participants in the SBR groups (Phase 2 Treatment Group 3 and Phase 3 Treatment Group 2 will also receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2 of EP). |
Tablets administered orally without regard to food
다른 이름들:
Tablets administered orally without regard to food
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Phase 2: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 24 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm
기간: Week 24
|
Participants who had the last available on-treatment HIV-1 RNA≥ 50 copies/mL in the week 24 analysis window, or who did not have on-treatment HIV-1 RNA data in the week 24 analysis window and participants who discontinued study drug prior to or in the week 24 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the week 24 analysis window due to adverse event (AE) or death and have the last available on-treatment HIV-1 RNA≥ 50 copies/mL, or who discontinued study drug prior to or in the week 24 analysis window due to reasons other than AE, death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 24 window for snapshot algorithm was between Days 127 and 210 (inclusively). Percentages were rounded off. |
Week 24
|
|
Phase 3: Percentages of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm
기간: Week 48
|
Participants who had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 48 analysis window, or who did not have on-treatment HIV-1 RNA data in the Week 48 analysis window and who discontinued study drug prior to or in the Week 48 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the Week 48 analysis window due to AE or death and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL, or who discontinued study drug prior to or in the Week 48 analysis window due to reasons other than AE, death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively). Percentages were rounded off. |
Week 48
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Phase 2: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Determined by the US FDA-defined Snapshot Algorithm
기간: Week 24
|
Participants who had the last available on-treatment HIV-1 RNA < 50 copies/mL in the Week 24 analysis window were included. The Week 24 window for snapshot algorithm was between Days 127 and 210 (inclusively). Percentages were rounded off. |
Week 24
|
|
Phase 2: Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 24
기간: Baseline, Week 24
|
Baseline, Week 24
|
|
|
Phase 2: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) Through Week 24
기간: First dose date up to Week 24
|
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC+LEN or BIC/LEN FDC) or 30 days (for SBR) or any AE leading to study drug discontinuation. Percentages were rounded off. |
First dose date up to Week 24
|
|
Phase 2: PK Parameter: Cmax for Bictegravir (BIC) at Steady State
기간: At Week 16 or 24
|
Cmax is defined as the maximum observed concentration of drug. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit. |
At Week 16 or 24
|
|
Phase 2: PK Parameter: Cmax for Lenacapavir (LEN) at Steady State
기간: At Week 16 or Week 24
|
Cmax is defined as the maximum observed concentration of drug. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit. |
At Week 16 or Week 24
|
|
Phase 2: PK Parameter: AUCtau of BIC at Steady State
기간: At Week 16 or 24
|
AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit. |
At Week 16 or 24
|
|
Phase 2: PK Parameter: AUCtau for LEN at Steady State
기간: At Week 16 or Week 24
|
AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit. |
At Week 16 or Week 24
|
|
Phase 2: PK Parameter: Ctrough of BIC at Steady State
기간: At Week 16 or Week 24
|
Ctrough is defined as the observed drug concentration at the end of the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit. |
At Week 16 or Week 24
|
|
Phase 2: PK Parameter: Ctrough of LEN at Steady State
기간: At Week 16 or Week 24
|
Ctrough is defined as the observed drug concentration at the end of the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit. |
At Week 16 or Week 24
|
|
Phase 3: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm
기간: Week 48
|
Participants who had the last available on-treatment HIV-1 RNA < 50 copies/mL in the Week 48 analysis window were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively). |
Week 48
|
|
Phase 3: Change From Baseline in CD4 Cell Count at Week 48
기간: Baseline, Week 48
|
An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC+LEN or BIC/LEN FDC) or 30 days (for SBR) or any AE leading to study drug discontinuation. Percentages were rounded off. |
Baseline, Week 48
|
|
Phase 3: Percentage of Participants Experiencing TEAEs Through Week 48
기간: First dose date up to Week 48
|
An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as 1 or both of the following: Any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. Percentages were rounded off. |
First dose date up to Week 48
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 96 as Determined by the US FDA-defined Snapshot Algorithm
기간: Week 96
|
Week 96
|
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 144 as Determined by the US FDA-defined Snapshot Algorithm
기간: Week 144
|
Week 144
|
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Determined by the US FDA-defined Snapshot Algorithm
기간: Week 96
|
Week 96
|
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 144 as Determined by the US FDA-defined Snapshot Algorithm
기간: Week 144
|
Week 144
|
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Change From Baseline in CD4 Cell Count at Week 96
기간: Baseline, Week 96
|
Baseline, Week 96
|
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Change From Baseline in CD4 Cell Count at Week 144
기간: Baseline, Week 144
|
Baseline, Week 144
|
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants Experiencing TEAEs Through Week 96
기간: Week 96
|
Week 96
|
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants Experiencing TEAEs Through Week 144
기간: Week 144
|
Week 144
|
공동 작업자 및 조사자
간행물 및 유용한 링크
일반 간행물
- Arora P, Hindman JT, West S, Ling J, Palaparthy R, Marathe DD. The effect of antacid and mineral supplements on bictegravir pharmacokinetics: results from a Phase 1, open-label, drug-drug interaction study. Antimicrob Agents Chemother. 2026 Jan 7;70(1):e0078125. doi: 10.1128/aac.00781-25. Epub 2025 Nov 28.
- Orkin C, Ruane PJ, Hedgcock M, Gaultier C, Losso MH, Trottier B, Lutz T, O'Reilly M, Bloch M, Slim J, Ramgopal M, Sokhela S, Mounzer K, Tsai HC, Santana Bagur J, Zhang X, Aizen K, Price K, Margot N, Montezuma-Rusca JM, Sklar P, Rhee M, Cahn P; ARTISTRY-1 Study Group. Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial. Lancet. 2026 Mar 28;407(10535):1249-1258. doi: 10.1016/S0140-6736(26)00307-7. Epub 2026 Feb 25.
- Ph2 PK data was included as part of the 2024 HIV-G presentation: https://hivglasgow.org/wp-content/uploads/2025/02/P049_Arora.pdf
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- GS-US-621-6289
- 2022-500929-33 (기타 식별자: European Medicines Agency)
- DOH-27-052023-8574 (기타 식별자: South African Clinical Trial Registry)
- jRCT2051230168 (기타 식별자: Japan registry)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .